Cyclic hexapeptides designed at the Monash Institute of Pharmaceutical Sciences to mimic the LEDGF/p75 binding domain disrupt the interaction between that host protein and HIV-1 integrase, but they bind with low affinity and no quantitative data have been disclosed. The compounds are a credible…
Cyclic hexapeptides that structurally mimic the LEDGF/p75 binding domain can disrupt the interaction between that host protein and HIV-1 integrase, according to research at the Monash Institute of Pharmaceutical Sciences in Australia, as reported in a vendor research summary published December 7, 2018. The same report states that the peptides do so with low affinity. No numeric affinity value, no assay format, and no peptide sequences are given. The compounds are therefore a credible chemical starting point for an integrase-targeting anti-HIV strategy, and nothing more. Reaching drug-level potency will require attaching additional molecular interactions to the six-residue ring.
This article lays out what the Monash result does and does not show and sets it against the published literature on cyclic hexapeptides as drug scaffolds. It closes with the measurements a researcher would need before treating this class as a genuine lead series.
HIV-1 integrase mediates the integration of proviral DNA into the host genome, the step that turns a transient viral infection into a permanent one. The enzyme first trims the viral DNA ends and then joins them into host chromosomal DNA. Blocking that step is an established approach in HIV drug development; integrase strand transfer inhibitors are a standard component of antiretroviral regimens. Those drugs occupy the catalytic active site of the enzyme. The Monash work targets a different surface: the protein-protein interface where integrase meets the host factor LEDGF/p75.
LEDGF/p75, lens epithelium-derived growth factor, is a key host protein involved in viral import. It binds HIV-1 integrase, and the interaction helps direct the viral integration machinery to the host genome. Disrupting this integrase-host interaction is intended to impair viral integration and thereby inhibit infection. Because the interaction is between two proteins, it is a harder target than an enzyme active site. Protein-protein interfaces are large and flat, and the contacts that drive binding are spread across a wide surface rather than concentrated in a deep pocket.
Targeting a host protein also carries a theoretical advantage over targeting the viral enzyme. Integrase mutates under drug pressure, and resistance to active-site inhibitors is a documented clinical problem. The LEDGF/p75 binding surface on integrase is under selection too, but the host protein itself does not mutate to accommodate the virus. A molecule that competes with LEDGF/p75 for the same surface could in principle retain activity against integrase variants that evade active-site inhibitors. That rationale remains speculative for these particular peptides, since their affinity is far too low to test the idea in cells.
The difficulty of the protein-protein target is real but not absolute. Most interfaces carry a small number of hot spots, residues that contribute a disproportionate share of the binding free energy. A molecule that reproduces a hot spot can capture a meaningful fraction of that energy, provided it presents the relevant side chains in the right geometry without paying a large entropic penalty to adopt that geometry on binding. Cyclic peptides address precisely this problem. Covalently closing a short peptide into a ring preorganizes its backbone, fixes the relative positions of the side chains, and reduces the entropic cost of binding, which is why macrocycles have become a favored format for mimicking protein epitopes.
That is the design logic behind the Monash compounds. The researchers built cyclic hexapeptides, rings of 6 amino acid residues, that closely mimic the structure of the LEDGF/p75 binding domain. The rings present the same side chains in the same spatial arrangement that LEDGF/p75 uses to contact integrase, so they compete with the full-length host protein for the same binding surface on integrase. If they bind well enough, they block the host protein from directing the viral integration machinery, and the virus cannot establish a productive integration event.
The limitation of the approach is equally clear from the design. A six-residue macrocycle is small relative to the full LEDGF/p75 contact surface. It can cover only part of the interface, which means it should bind more weakly than the full-length protein. The measured outcome reported by Monash, low affinity, matches that expectation.
The central claims in the Monash report are specific and modest. The peptides are cyclic hexapeptides, so each ring contains exactly 6 amino acid residues. They closely mimic the LEDGF/p75 binding domain. They disrupt the integrase-LEDGF/p75 interaction. Their affinity for that interaction is low. From those low affinities, the researchers conclude that additional molecular interactions must be incorporated before the peptides reach the potency an effective drug would require.
Each claim is plausible, and each is thinly supported by the public record. The reader is not told which integrase construct was used, whether the assay was biochemical or cellular, what the measured dissociation constant was, or which sequences were tested. "Low" is a qualitative verdict, not a result. The full research may well be published elsewhere, but the report on which this article is based does not provide the numbers, and a vendor research summary is not a peer-reviewed study.
What the report does establish is the direction of the chemistry. A cyclic hexapeptide can be built that engages the integrase surface recognized by LEDGF/p75. That is not trivial. Protein-protein interaction mimics usually stop binding entirely when shrunk to six residues, because most of the buried surface area is sacrificed. That the peptides bind at all, even weakly, indicates the LEDGF/p75 binding domain carries a dominant hot spot that a small ring can reproduce. That is the useful scientific content of the result.
The potency gap is the expected consequence of the design. The integrase-LEDGF/p75 interface buries a large surface, and a mimic of only one binding domain covers a fraction of it. Binding free energy scales with buried surface area, so a domain mimic should bind more weakly than the full-length protein. The Monash conclusion, that more interaction surfaces are needed, follows directly from the geometry. The open question is which surfaces to add and how to attach them to a cyclic scaffold without destroying the exact side-chain arrangement that produced the initial binding.
To see why the potency gap matters, it helps to place "low" in context. Protein-protein interaction inhibitors that advance toward the clinic typically begin as hits in the low micromolar range and are optimized to nanomolar or better. The Monash report does not place its compounds on that scale, so the distance to a drug candidate cannot be measured. What can be said is that a peptide with low affinity for a cellular protein-protein interaction would need both a large improvement in binding and demonstrable activity in cells before it could be called a lead. The absence of sequence information also means the compounds cannot be compared with other integrase-binding peptides in the literature, a real limitation for anyone trying to assess novelty or overlap.
The Monash compounds belong to a well-studied chemical class. Cyclic hexapeptides are small, synthetically accessible macrocycles with a demonstrated record of biological activity. The indexed literature offers context for judging whether the potency gap is a solvable engineering problem or a dead end.
| Source | Scope | Key finding | Relevance |
|---|---|---|---|
| PMID 7527014 | Eleven cyclic hexapeptide NK-2 receptor antagonists | Binding affinities of 7 × 10^-7 to 1 × 10^-8 M; pA2 values of 7.1 to 7.8; diverse side chains tolerated at one position | Cyclic hexapeptides can reach nanomolar affinity at a protein target |
| PMID 31042375 | Eight cyclic hexapeptide diastereomers, computational permeability study | Average solvent-accessible surface area in cyclohexane correlated with experimental cell permeability; polar surface area did not | Solvent-dependent conformations can predict membrane permeability |
| PMID 27031286 | Conformational dynamics of cyclic hexapeptides | Conformational switching proceeds via coupled rotations of two adjacent backbone dihedrals | Provides a mechanistic description of cyclic hexapeptide backbone conformational change |
| PMID 34244894 | Antitumor bicyclic hexapeptide RA-VII and analogues | Synthetic route to cycloisodityrosines from L-tyrosine derivatives | The scaffold is tractable to synthesis and structure-activity optimization |
| PMID 38629756 | Antatollamides A and B | Structures revised from dimeric disulfide-bridged peptides to monomeric cyclic hexapeptides | Shows structural revision can be accomplished by synthesis and NMR comparison |
| PMID 37550948 | Meristosporins A-C from Basidiobolus meristosporus | New cyclic peptides; meristosporins A and B cytotoxic against RAW264.7 and 293T cells | Natural cyclic peptides show bioactivity in mammalian cell assays |
The NK-2 antagonist series is a benchmark for the potency question. Eleven cyclic hexapeptides, including N-glycosylated variants, were selective NK-2 receptor antagonists with binding affinities of 7 × 10^-7 to 1 × 10^-8 M and pA2 values of 7.1 to 7.8, and the series tolerated a range of side chains at the glutamine position without major loss of activity PMID 7527014 . Receptor binding sites are more druggable than protein-protein interfaces, so the comparison is not direct. But the result shows that a cyclic hexapeptide scaffold can, after optimization, deliver single-digit nanomolar affinity. The Monash peptides sit far from that range, and the gap reflects the difficulty of the protein-protein target as much as the immaturity of the series.
The NK-2 series also carries a design lesson for the integrase problem. Because one position on the ring tolerated a variety of side chains without destroying affinity, a medicinal chemist can treat that position as a handle for tuning pharmacokinetics or adding new contacts. By analogy, systematic single-position scanning around the LEDGF mimic would be a sensible early step for the Monash series, mapping which ring positions tolerate substitution and which must be preserved exactly.
Permeability is the second design consideration. For a peptide to act against HIV, it must reach the inside of an infected cell, where integration takes place. In a computational study of eight cyclic hexapeptide diastereomers, the average solvent-accessible surface area in cyclohexane correlated strongly with experimental cell permeability, whereas polar surface area did not PMID 31042375 . Permeability depends on the conformational ensemble the peptide adopts in a low-dielectric environment, not on a static surface measurement. A companion study showed that cyclic hexapeptides switch conformations through local coupled rotations of two adjacent backbone dihedrals, a mechanism that can be exploited to improve conformational sampling in simulations PMID 27031286 .
The conformational switching work carries its own design lesson. Because cyclic hexapeptides populate discrete conformations that interconvert through coupled backbone rotations, small changes in ring chemistry can shift the population between a binding-competent shape and a permeable one. Rigidifying the ring into the binding conformation can improve affinity and permeability at once, but only if the rigidity is placed where it does not disturb the side chains that mimic LEDGF/p75. Measuring the conformation-permeability relationship of each analog early is the practical takeaway.
The remaining entries document the practicality of the scaffold. The antitumor bicyclic hexapeptide RA-VII, from Rubiae radix, has supported structure-activity studies through an efficient synthetic route to cycloisodityrosines from L-tyrosine derivatives PMID 34244894 , showing that complex cyclic hexapeptide architectures are synthesizable. The structural revision of antatollamides A and B, from proposed dimeric disulfide-bridged structures to monomeric cyclic hexapeptides, is a cautionary tale: the initially proposed structures proved incorrect, and synthesis with NMR comparison was needed to establish the correct structures PMID 38629756 . Natural product discovery continues to add bioactive members, including meristosporins A-C from the fungus Basidiobolus meristosporus, two of which showed cytotoxicity against RAW264.7 and 293T cells PMID 37550948 . None of these studies involve HIV integrase. They support the class-level claim that cyclic hexapeptides are viable, optimizable drug scaffolds, while warning that structure assignment and permeability are nontrivial.
A researcher who wants to build on the Monash result should treat it as a starting point with known weaknesses. The steps below are the minimum needed to convert a weak cyclic hexapeptide integrase binder into a credible lead series.
Quantify the interaction first. The report discloses no affinity value. Before any medicinal chemistry, the series needs a reproducible binding assay, ideally with a purified LEDGF/p75 binding domain as a competitor and a defined integrase construct, and reporting a dissociation constant in molar units. Surface plasmon resonance, isothermal titration calorimetry, or a validated fluorescence polarization assay would all serve. The assay should also confirm that the peptide blocks the interaction with full-length LEDGF/p75, not merely a truncated domain.
Optimize against the full interface. A six-residue ring mimicking only the LEDGF/p75 binding domain is expected to be weak, and the Monash conclusion about adding interactions is the correct design principle. Options include exocyclic extensions that reach adjacent regions of the integrase surface, a second ring, a stapled segment, or a peptidomimetic that presents the LEDGF side chains with additional contacts in the same macrocycle. The NK-2 antagonist series demonstrates that side-chain positions in cyclic hexapeptides tolerate variation PMID 7527014 , which is useful for building a structure-activity matrix around the initial hit.
Track permeability from the start. The cyclohexane surface-area correlation PMID 31042375 shows that average solvent-accessible surface area in cyclohexane correlates with cell permeability, and the coupled-rotation switching mechanism PMID 27031286 shows that cyclic hexapeptides switch conformations through coupled rotations of two adjacent backbone dihedrals. The practical conclusion: measure the conformational ensemble of each analog in a membrane-mimetic solvent, and do not assume that added potency will preserve permeability.
Test selectivity against related surfaces. A peptide that mimics a protein surface may stick to other surfaces with similar topography. The NK-2 series demonstrated target selectivity within a receptor family PMID 7527014 , but for integrase, selectivity must be demonstrated, not assumed. Counter-screens against other protein-protein interfaces of the preintegration complex would be appropriate as soon as affinity improves.
Move to cells only after the affinity is real. No cellular or in vivo efficacy data were reported for the Monash peptides. A compound with low affinity for a protein-protein interaction is unlikely to show antiviral activity at achievable concentrations, so cellular work should wait until the binding assay shows genuinely improved numbers.
Verify structures rigorously. The antatollamide revision PMID 38629756 is a reminder that cyclic peptide structure assignment can be wrong. Confirmation by synthesis and NMR comparison should be the standard before any claimed sequence or ring geometry is published or used as the basis for further design.
Locate the primary report. The vendor summary contains no sequences and no data. Anyone planning to reproduce or extend this work should find the peer-reviewed publication from the Monash group and obtain the compounds and assay details directly.
The gaps in the public record are substantial. The specific amino acid sequences of the Monash cyclic hexapeptides are not disclosed. The exact affinity values, the integrase construct used, the buffer and assay conditions, and the confirmation that the peptides compete with full-length LEDGF/p75 are unknown. The design of the additional molecular interactions needed to reach potency is described only as a direction, not as a concrete plan. Whether optimized analogs could achieve the potency and selectivity required to advance toward preclinical development is entirely open.
The evidence base has three structural limits. First, the source is a vendor research summary published December 7, 2018, not a peer-reviewed study, and it omits the experimental detail needed to evaluate the claim independently. Second, no in vivo or cellular efficacy data are presented, so even the weak binding is not connected to antiviral activity. Third, the indexed peer-reviewed literature on cyclic hexapeptides concerns other targets and other compounds; it contextualizes the scaffold but cannot substitute for a peer-reviewed report of the integrase work.
A useful follow-up report from the Monash group would include the peptide sequences, a quantitative binding constant measured against a defined integrase construct, competition data against full-length LEDGF/p75, a cellular integration or replication assay, and a permeability measurement. A competition experiment would settle whether the peptides occupy the same surface the host protein uses, and a cellular integration assay would settle whether the weak binding translates into any antiviral effect. Without those, the appropriate assessment is that cyclic hexapeptide mimics of the LEDGF/p75 binding domain are a plausible but unproven chemical starting point for integrase-targeting HIV therapeutics. They are not yet drug candidates.
PMID 7527014 - Cyclic hexapeptide NK-2 antagonists. International Journal of Peptide and Protein Research, 1994. https://pubmed.ncbi.nlm.nih.gov/7527014/
PMID 31042375 - Conformation and Permeability: Cyclic Hexapeptide Diastereomers. Journal of Chemical Information and Modeling, 2019. https://pubmed.ncbi.nlm.nih.gov/31042375/
PMID 27031286 - Insights into How Cyclic Peptides Switch Conformations. Journal of Chemical Theory and Computation, 2016. https://pubmed.ncbi.nlm.nih.gov/27031286/
PMID 34244894 - Design and Synthesis of Analogues of RA-VII, an Antitumor Bicyclic Hexapeptide from Rubiae Radix. Journal of Natural Medicines, 2021. https://pubmed.ncbi.nlm.nih.gov/34244894/
PMID 38629756 - Synthesis and Structural Revision of the Cyclic Hexapeptide Dimers Antatollamides A and B. Organic Letters, 2024. https://pubmed.ncbi.nlm.nih.gov/38629756/
PMID 37550948 - Cyclic Peptides from the Opportunistic Pathogen Basidiobolus meristosporus. Journal of Natural Products, 2023. https://pubmed.ncbi.nlm.nih.gov/37550948/
Related reading: CAPA tracks biotherapeutic cell uptake and organelle distribution, Prepacked OptioBio Columns for Small-Scale IEX and Process Development, Peptide Therapeutics' Golden Age: Synthesis Advances, CMC Demands, Minimizing Aggregation in Protein A Elution: pH and Buffer.